Anticoagulants Improve Survival Rates in Patients With COVID-19

June 01, 2020

Researchers from the Mount Sinai COVID Informatics Center report improved survival rates in COVID patients treated with anticoagulants.

Time of Day for Taking Warfarin Does Not Affect Anticoagulation Stability

January 27, 2020

Administration time for warfarin did not affect the stability of the drug’s anticoagulation effect, a new study showed. 

Crizanlizumab for Sickle Cell Pain Reduction Approved by FDA

November 15, 2019

First and currently only biological targeting P-selectin.

Wilate Approved for Hemophilia A Treatment

October 09, 2019

Also indciated to control bleeding and perioperative management.

New Warnings for Tofacitinib Issued by FDA

July 29, 2019

Black box warns of increased risk of blood clots and death.

Study: VKAs Better Protect Aortic Valve Replacement Patients

June 14, 2019

Study finds higher Ischemic events and mortality in transcatheter valve replacement patients taking non-vitamin K antagonist oral anticoagulants versus vitamin K antagonists.

AF Patients Taking OACs Have Lower Dementia Risk

June 14, 2019

Low-risk atrial fibrillation patients who take oral anticoagulants have a lower risk of dementia than those who do not, a study says.

DOAC Use Increasing in Nursing Homes

May 24, 2019

The use of direct‐acting oral anticoagulants has increased among nursing home residents with atrial fibrillation.

Atrial Fibrillation Patients Often Overestimate Stroke and Bleeding Risks

May 24, 2019

Overestimating the bleeding risk of anticoagulants may lead to poor compliance.

FDA Approves Fragmin as First Pediatric Anticoagulant Treatment

May 16, 2019

Fragmin, a low-molecular-weight heparin dalteparin sodium injection, was approved for symptomatic venous thromboembolism.

Bleeding Improved with Apixaban versus VKA

April 22, 2019

Bleeding in patients with nonvalvular atrial fibrillation and coronary syndrome was reduced by apixaban versus vitamin K antagonists.

Kidney Disease Patients May Not Be Getting OACs

April 22, 2019

Many kidney disease patients with atrial fibrillation are not treated with anticoagulation, increasing their risk of stroke.

Patients with Cognitive Impairment Less Likely to Get OACs

March 15, 2019

Study finds different anticoagulation treatment levels for patients with cognitive problems.

Two Studies Show Efficacy of Rivaroxaban, Other NOACs in Preventing Stroke

March 15, 2019

A meta-analysis of 95 studies indicates lower risk of stroke and intracranial hemorrhage.

Increased Risk of Blood Clots and Death Seen with Higher Dose Tofacitinib

February 26, 2019

Higher-dose tofacitinib linked to greater risk of pulmonary embolism in RA patients.

Cablivi for Acquired Thrombotic Thrombocytopenic purpura

February 18, 2019

What you need to know about the von Willebrand factor (vWF)-directed antibody fragment.

Study: DOACs Equal to or Better Than Warfarin

February 16, 2019

DOACs are as good as warfarin in preventing atrial fibrillation complications.

New Guidelines: NOACs Preferred Over Warfarin in AFib

February 16, 2019

Three cardiology groups now recommend using NOACs over warfarin in atrial fibrillation.

Racial Disparities Found in Oral Anticoagulant Prescription Patterns

January 14, 2019

Black patients with atrial fibrillation are less likely to be treated with oral anticoagulants or DOACs.

Choice of Anticoagulant and Cotherapy with a PPI Affect Gastrointestinal Bleeding Risk

January 11, 2019

The risk of gastrointestinal bleeding appears to be highest with rivaroxaban and lowest with apixaban, but is reduced by cotherapy with proton pump inhibitors.